Wondering if Axogen at around US$31.32 is still offering value or if the easy gains are behind it? This article walks through what the current price actually reflects.
The stock has had a mixed recent run, with a 4.0% decline over the last week and a 1.3% decline over the last month, while still sitting on a 1.0% return year to date and a 75.9% return over the last year.
Those moves sit within a longer track record that includes a 223.2% return over three years and a 56.8% return over five...
Wondering if Cactus at around US$46.70 is priced attractively or already reflects its strengths? This article walks through the key signals that matter for valuation-focused investors.
The stock has seen a 2.2% decline over the last week and a 13.5% decline over the last month, while still showing returns of 3.2% over 1 year, 11.4% over 3 years and 58.7% over 5 years.
These moves sit against a backdrop where investors are watching sector-wide sentiment and company-specific developments...
Fermi has yet to secure a cornerstone tenant for its flagship Project Matador campus, despite progressing permits that target 17 GW of power capacity.
The company has made substantial capital commitments and lined up equipment financing, but no anchor customer contract has been confirmed.
This gap between infrastructure build out and tenant sign on is raising questions about future revenue visibility and the private grid model.
For investors watching NasdaqGS:FRMI, the lack of an anchor...
Commercial Metals increased its regular quarterly dividend for the 246th consecutive quarter.
The latest dividend raise extends a multidecade record of uninterrupted quarterly increases.
The move signals continued commitment to returning cash to shareholders.
For investors watching NYSE:CMC, this dividend hike arrives with the stock trading around $60.09. The share price has seen a 31.8% gain over the past year and a 103.2% gain over the past five years, while the year-to-date return stands...
Index removal puts fresh focus on Ziff Davis
Ziff Davis (ZD) has been removed from the NASDAQ Internet Index, an adjustment that can prompt portfolio shifts for index-tracking funds and encourage investors to reassess how the stock fits within internet sector exposures.
See our latest analysis for Ziff Davis.
The latest index exit comes after a sharp 54.8% 30 day share price return, alongside a 23.3% year to date share price gain. The 1 year total shareholder return of 11.6% contrasts with a...
Sigma Lithium (NasdaqCM:SGML) just posted its FY 2025 third quarter scorecard with revenue of US$28.5 million and a basic EPS loss of US$0.10, alongside net income excluding extra items of a US$11.6 million loss. The company has seen quarterly revenue move between US$16.9 million and US$47.7 million over the past three reported quarters, with basic EPS ranging from a profit of US$0.04 to losses of US$0.17. Trailing twelve month EPS stands at a loss of US$0.30 on revenue of US$139.0 million...
In March 2026, Protagonist Therapeutics reported one-year Phase 3 data for ICOTYDE (icotrokinra) in moderate to severe plaque psoriasis, showing sustained skin clearance and a favorable safety profile as the first oral IL-23 receptor–targeted peptide.
The data, including adolescent results through Week 52, underline ICOTYDE’s potential as a once-daily pill alternative to injectable treatments and highlight the company’s peptide discovery platform.
We’ll now look at how ICOTYDE’s...
At the March 12, 2026 BofA Securities Information & Business Services Conference, First Advantage Corporation highlighted 17% fourth-quarter revenue growth, a transition toward capital risk management solutions, and board approval of a US$100,000,000 share repurchase program.
The company’s emphasis on expanding beyond background screening into a broader capital risk management platform, supported by about 97% client retention, underlines management’s confidence in scaling the business...
Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months.
See our latest analysis for Arcellx.
Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum...
What Gevo’s North Dakota expansion announcement means for the stock
Gevo (GEVO) has attracted fresh attention after outlining plans to potentially add a second low carbon ethanol plant at its North Dakota site. This would more than double the current nameplate capacity.
See our latest analysis for Gevo.
The expansion news arrives after a strong run in the shares, with a 30 day share price return of 38.46% and a year to date share price return of 22.33%, while the 1 year total shareholder...
Over the last 7 days, the United States market has dropped 1.9%, yet it remains up by 15% over the past year with earnings forecasted to grow by 15% annually, indicating a resilient and optimistic outlook for investors. In this context, identifying high growth tech stocks involves assessing companies that not only capitalize on technological advancements but also demonstrate strong potential for sustained revenue and earnings growth in line with or exceeding these market trends.
Over the last 7 days, the United States market has experienced a 1.9% decline; however, it remains up by 15% over the past year with earnings projected to grow by 15% annually. In this context, identifying stocks that are trading at significant discounts can present valuable opportunities for investors seeking to capitalize on potential growth while navigating current market fluctuations.
Over the last 7 days, the United States market has experienced a 1.9% drop, yet it remains up by 15% over the past year with earnings projected to grow by 15% annually in the coming years. In this environment, identifying growth companies with high insider ownership can be particularly appealing as it suggests management's confidence in their long-term potential amidst these fluctuating market conditions.
Over the last 7 days, the United States market has experienced a 1.9% drop, yet it remains up by 15% over the past year with earnings projected to grow annually by the same percentage. In this dynamic environment, identifying stocks that are not only resilient but also positioned for growth can be crucial for investors seeking opportunities beyond well-trodden paths.
Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with annual earnings growth forecasted at 15%. In this dynamic environment, identifying dividend stocks that offer reliable income and potential for capital appreciation can be an effective strategy for investors seeking stability and growth.
In recent months, Janus Henderson’s Forty Fund highlighted Madrigal Pharmaceuticals’ success with Rezdiffra, the first FDA-approved MASH therapy, while the company also signed a global licensing deal with Suzhou Ribo Life Science and Ribocure for six preclinical siRNA programs targeting metabolic liver disease.
Together, strong early Rezdiffra adoption and an expanded siRNA pipeline suggest Madrigal is moving from a single-product story toward a broader MASH-focused franchise.
Next, we’ll...
Earlier this month, Vaxcyte announced it had fully enrolled its OPUS-1 and OPUS-2 Phase 3 trials of VAX-31, a 31-valent pneumococcal conjugate vaccine for adults, and recently published positive Phase 1/2 VAX-31 data in The Lancet Infectious Diseases.
These milestones, together with FDA-aligned Phase 3 designs intended to support a future Biologics License Application, underscore VAX-31’s potential to broaden pneumococcal disease coverage versus existing adult vaccines.
We’ll now examine how...
Corebridge Financial stock: recent performance snapshot
Corebridge Financial (CRBG) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month, past 3 months and year to date, prompting investors to reassess its risk and return trade off.
See our latest analysis for Corebridge Financial.
At a share price of US$22.30, Corebridge Financial has seen momentum fade recently, with a 30 day share price return of 13.70% decline and a 1 year...
United Therapeutics reported positive phase 3 results from its TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF).
The trial met its primary efficacy endpoint and showed significant benefits over placebo with a favorable safety profile.
The company plans to seek a supplemental FDA approval to add IPF to the Tyvaso label, supported by integrated data from TETON-1 and TETON-2.
For investors watching United Therapeutics, ticker NasdaqGS:UTHR, this news arrives with the...
Wondering if Atlanta Braves Holdings at around US$41.53 is offering good value or just a fan premium? This breakdown is designed to help you see what the current price really represents.
The stock has seen a 1% decline over the last 7 days and a 5% decline over the last 30 days, while still showing returns of 4.2% year to date, 3.8% over 1 year, 23.2% over 3 years and 43.2% over 5 years.
Recent coverage has focused on the company as a way to gain exposure to a well known sports franchise...
Wondering if Clearwater Analytics Holdings at around US$23.49 is offering good value right now, or if the price already reflects most of the upside you care about.
The stock has been relatively steady in the near term, with a 0.9% return over the last 7 days and 0.4% over the last 30 days, while year to date it shows a 2.6% decline and the 1 year return sits at a 12.4% decline, compared with a 48.6% gain over 3 years.
Recent coverage has focused on Clearwater Analytics Holdings as a listed...
